NTHI — NeOnc Technologies Holdings, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$4.61
+$0.04 (+0.99%)
NeOnc Technologies Holdings, Inc. Common Stock (NTHI) is a biotechnology company listed on NASDAQ. It is led by Amir Farrokh Heshmatpour, based in 23975 Park Sorrento, Calabasas, CA, United States, 91302, with about 5 employees. NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Latest reported NTHI revenue for 2025-09-30 was $40.0K. Net income was -$8.6M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. NTHI currently screens at market cap $117.3M.
Use this NTHI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NTHI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NTHI SEC filings page. Lician reads the product cache first so this HTML stays unique to NeOnc Technologies Holdings, Inc. Common Stock even when a live quote feed is slow.
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
NTHI Key Statistics
Market Cap
$117.32M
Volume
99,899
Previous Close
$4.56
Day Range
$4.49 – $4.76
EPS
-$0.45
Revenue
$39.99K
Net Income
-$8.62M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+0.0%
Profit Margin
-21545.2%
Employees
5
NTHI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2025 | FY2025 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $39.99K | $39.99K | $39.99K | $63.00K | $20.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.62M | -$5.68M | -$32.33M | -$2.18M | -$4.52M |
| EPS (Diluted) | -$0.45 | -$0.30 | -$2.10 | -$0.12 | -$0.27 |
Total Assets
$4.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.51M
Operating Cash Flow
-$16.77M
Free Cash Flow
$0.00
NeOnc Technologies Holdings, Inc. Common Stock Company Information
- President, CEO, Executive Chairman & Secretary
- Amir Farrokh Heshmatpour
- Headquarters
- 23975 Park Sorrento, Calabasas, CA, United States, 91302
- Website
- www.neonc.com
- Phone
- 310 663 7831
- IPO / Founded
- 2025-03-26
- Sector
- Healthcare
- Industry
- Biotechnology